Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The study's purpose is to understand the appearance of your prostate-specific membrane
antigen (PSMA) PET scan after you take 14 days of treatment with a drug called dasatinib
alone or in combination with anti-testosterone drug call darolutamide.
Who is it for? You may be eligible to join this study if you have metastatic prostate cancer
and had a recent PSMA scan showing low PSMA uptake
Study Details:
Participants will receive dasatinib 100 mg daily or dasatinib 100 mg daily and darolutamide
600 mg twice daily for 14 days. They will undergo another PSMA PET scan after 14 days.
Participants will be followed up on day 7 of treatment and 30 days after treatment.
It is hoped that this research will provide insight into the mechanism of PSMA expression in
advanced prostate cancer.